Skip to main
BCAX
BCAX logo

BCAX Stock Forecast & Price Target

BCAX Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 60%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Bicara Therapeutics Inc. shows a promising outlook due to the efficacy of its bifunctional therapy, ficerafusp alfa, which demonstrates a significantly higher objective response rate (ORR) compared to established treatments like Keytruda. Specifically, ficerafusp alfa achieved superior clinical outcomes with notable metrics, such as a median progression-free survival (mPFS) of 9.9 months and a median overall survival (mOS) of 21.3 months, enhancing its therapeutic profile against similar patient populations. The comparative advantage in survival metrics implies a potential shift in treatment standards for patients with solid tumors, further supporting positive sentiment towards the stock.

Bears say

Bicara Therapeutics reported a net loss of $0.50 per share for the second quarter of 2025, aligning closely with prior estimates, and projects a full-year loss of $2.27 per share, a slight improvement from previous forecasts. The company faces significant risks, including the potential for negative clinical results with its lead program ficerafusp alfa, delays in moving the treatment to registrational trials, and challenges in achieving timely regulatory approvals. Furthermore, the competitive landscape poses additional challenges, with risks of long-term dilution also impacting investor sentiment regarding the stock.

BCAX has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 60% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicara Therapeutics Inc (BCAX) Forecast

Analysts have given BCAX a Buy based on their latest research and market trends.

According to 5 analysts, BCAX has a Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicara Therapeutics Inc (BCAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.